Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 385, Issue 16, Pages 1531-1533Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMc2112411
Keywords
-
Categories
Funding
- Boehringer Ingelheim
- Eli Lilly
Ask authors/readers for more resources
Empagliflozin had different effects on renal outcomes in heart failure patients between two trials, with major adverse renal outcomes occurring in 2.8% of patients who received the drug and 3.5% of those who received a placebo.
Empagliflozin and Renal Outcomes in Heart Failure In a planned pooled analysis of two trials that evaluated empagliflozin in patients with heart failure, major adverse renal outcomes occurred in 2.8% of the patients who received empagliflozin and in 3.5% of those who received placebo. Results differed between the two trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available